Study Examining The Effect Of Renal Impairment On Safety, Toleration And How The Body Processes An Experimental Drug

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 30, 2007

Primary Completion Date

October 31, 2008

Study Completion Date

October 31, 2008

Conditions

Obesity

Interventions

DRUG

CP-945,598

Administration of CP-945,598 in subjects with normal renal function.

DRUG

CP-945,598

Administration of CP-945,598 in subjects with severe renal impairment.

Trial Locations (2)

Pfizer Investigational Site, Miami

Pfizer Investigational Site, Anaheim